Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.25.2
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Jul. 31, 2025
Jul. 31, 2024
Oct. 31, 2024
Segment Reporting Information [Line Items]          
Net loss $ (2,280) $ (3,315) $ (8,306) $ (9,785)  
Total operating costs and expenses 2,436 3,592 8,825 10,668  
Less non-cash stock-based compensation (855) (1,179) (2,899) (3,699)  
Operating costs and expenses excluding non-cash stock-based compensation 1,581 2,413 5,926 6,969  
Total assets 17,651   17,651   $ 21,591
Cancer Vaccines [Member]          
Segment Reporting Information [Line Items]          
Net loss (1,298) (2,160) (5,195) (5,628)  
Operating costs and expenses excluding non-cash stock-based compensation 884 1,614 3,714 3,988  
Total assets 9,842   9,842   12,917
CAR-T Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net loss (973) (1,145) (3,074) (4,115)  
Operating costs and expenses excluding non-cash stock-based compensation 689 789 2,180 2,943  
Total assets 7,691   7,691   8,535
Other [Member]          
Segment Reporting Information [Line Items]          
Net loss (9) (10) (37) (42)  
Operating costs and expenses excluding non-cash stock-based compensation 8 $ 10 32 $ 38  
Total assets $ 118   $ 118   $ 139